Xilio Therapeutics Inc (XLO)
NASDAQ:XLO
Want to see XLO full AI Analyst Report?
Top Page
Xilio Therapeutics
(NASDAQ:XLO)
Select Model
Select Model
Rating:51Neutral
Price Target:
$9.00
▲(1425.42% Upside)
Action:Reiterated
Date:05/15/26
The score is held back primarily by persistent operating losses and substantial cash burn, which increase funding and execution risk. Offsetting these are strong revenue growth and high gross margins alongside low leverage. Technicals are moderately supportive (above shorter-term averages and RSI in a constructive zone), but valuation is constrained by negative earnings and the absence of dividend support.
Positive Factors
High gross margin and revenue growth
Sustained ~73% gross margins and ~22% TTM revenue growth indicate the company captures strong product/collaboration economics and is improving top-line traction. These durable margins support scalable profitability once clinical programs convert to commercial revenues or higher-value partnerships, reducing long-term margin risk versus peers.
Negative Factors
Persistent cash burn
Regular negative operating and free cash flow (~-$56M TTM) means the company must continually access external capital until programs commercialize. This elevates dilution and execution risk, forces capital-allocation tradeoffs, and creates sensitivity to funding markets or partner timing over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margin and revenue growth
Sustained ~73% gross margins and ~22% TTM revenue growth indicate the company captures strong product/collaboration economics and is improving top-line traction. These durable margins support scalable profitability once clinical programs convert to commercial revenues or higher-value partnerships, reducing long-term margin risk versus peers.
Read all positive factors
Xilio Therapeutics (XLO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$50.61M
Dividend YieldN/A
Average Volume (3M)55.45K
Price to Earnings (P/E)―
Beta (1Y)0.21
Revenue Growth476.71%
EPS Growth70.23%
CountryUS
Employees64
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.50
Shares Outstanding5,982,839
10 Day Avg. Volume101,149
30 Day Avg. Volume55,455
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)21.23
Price to Sales (P/S)17.11
P/FCF Ratio-135.93
Enterprise Value/Market Cap-1.84
Enterprise Value/Revenue-1.74
Enterprise Value/Gross Profit-2.46
Enterprise Value/Ebitda2.28
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.39
Revenue Forecast (FY)$27.31M
Xilio Therapeutics Business Overview & Revenue Model
Company Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is...
How the Company Makes Money
Xilio Therapeutics does not have recurring product revenue because it is a clinical-stage biotechnology company and, as of the latest publicly available information, has not commercialized any approved therapies. The company primarily funds operat...
Xilio Therapeutics Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 53.48M | 43.77M | 6.34M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 37.81M | 42.23M | 6.34M | 0.00 | 0.00 | -1.50M |
| EBITDA | -40.85M | -40.44M | -58.00M | -77.23M | -87.30M | -73.70M |
| Net Income | -31.30M | -35.04M | -58.24M | -76.40M | -88.22M | -75.80M |
Balance Sheet | ||||||
| Total Assets | 163.49M | 154.69M | 71.08M | 60.93M | 139.16M | 221.60M |
| Cash, Cash Equivalents and Short-Term Investments | 150.33M | 137.53M | 55.29M | 44.70M | 120.39M | 198.05M |
| Total Debt | 6.64M | 6.95M | 8.14M | 11.46M | 19.94M | 20.74M |
| Total Liabilities | 90.94M | 119.41M | 53.48M | 24.10M | 33.52M | 36.17M |
| Stockholders Equity | 72.55M | 35.27M | 17.60M | 36.83M | 105.65M | 185.43M |
Cash Flow | ||||||
| Free Cash Flow | -57.37M | -5.51M | -18.41M | -69.11M | -77.59M | -81.85M |
| Operating Cash Flow | -56.31M | -4.99M | -18.38M | -68.62M | -75.72M | -80.75M |
| Investing Cash Flow | -1.05M | -518.00K | -36.00K | -486.00K | -1.87M | -1.10M |
| Financing Cash Flow | 118.65M | 87.78M | 29.20M | -6.55M | -69.00K | 260.67M |
Xilio Therapeutics Technical Analysis
Positive
0.59
Price Trends
8.27
Positive
8.20
Positive
9.30
Negative
Market Momentum
0.08
Negative
54.45
Neutral
57.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XLO, the sentiment is Positive. The current price of 0.59 is below the 20-day moving average (MA) of 8.17, below the 50-day MA of 8.27, and below the 200-day MA of 9.30, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 54.45 is Neutral, neither overbought nor oversold. The STOCH value of 57.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XLO.
Xilio Therapeutics Risk Analysis
Xilio Therapeutics disclosed 86 risk factors in its most recent earnings report. Xilio Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Xilio Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $50.61M | -44.19 | -117.24% | ― | 476.71% | 70.23% | |
50 Neutral | $406.52M | -5.46 | -94.90% | ― | -71.26% | -300.04% | |
49 Neutral | $156.78M | -4.95 | -49.43% | ― | ― | ― | |
46 Neutral | $40.58M | -2.54 | -0.97% | ― | ― | 21.67% | |
45 Neutral | $390.53M | -44.84 | -106.16% | ― | ― | 63.03% | |
42 Neutral | $88.10M | -13.91 | 102.92% | ― | ― | ― |
* Healthcare Sector Average
XLO
Xilio Therapeutics
8.46
-1.34
-13.68%
FBRX
Forte Biosciences
19.07
10.24
115.97%
XFOR
X4 Pharmaceuticals
4.31
0.50
13.12%
LTRN
Lantern Pharma
3.59
0.40
12.54%
CNTB
Connect Biopharma Holdings
2.49
1.67
203.66%
OKYO
OKYO Pharma Limited Sponsored ADR
1.72
-0.03
-2.00%
Xilio Therapeutics Corporate Events
Executive/Board Changes
Xilio Therapeutics Announces Board Changes and Committee Leadership
Neutral
Apr 16, 2026
On April 15, 2026, Xilio Therapeutics appointed Cheryl R. Blanchard, Ph.D., as a Class III director with a term running through the 2027 annual meeting, while naming her chair of the Compensation Committee and a member of the Audit Committee. Her ...
Regulatory Filings and ComplianceShareholder MeetingsStock Split
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
Neutral
Mar 12, 2026
On March 12, 2026, Xilio Therapeutics announced that it would implement a 1-for-14 reverse stock split of its common shares, effective at 5:00 p.m. Eastern Time on March 13, 2026. The move, approved by stockholders at a special meeting on February...
Business Operations and StrategyPrivate Placements and Financing
Xilio Therapeutics Updates Investor Presentation on I-O Strategy
Positive
Mar 9, 2026
On March 9, 2026, Xilio Therapeutics posted an updated corporate investor presentation outlining its strategy to leverage clinically validated masking technology to develop tumor-selective immuno-oncology candidates, including vilastobart, efarind...
Shareholder MeetingsStock Split
Xilio Therapeutics Shareholders Approve Flexible Reverse Stock Split
Neutral
Feb 24, 2026
On February 23, 2026, Xilio Therapeutics, Inc. held a special meeting of stockholders at which investors approved an amendment to the company’s restated certificate of incorporation to enable a reverse stock split of its common shares at a r...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.